158 related articles for article (PubMed ID: 33817853)
1. Head-to-head trials in inflammatory bowel disease.
Radford-Smith G
J Gastroenterol Hepatol; 2021 Apr; 36 Suppl 1():18-19. PubMed ID: 33817853
[No Abstract] [Full Text] [Related]
2. The current state of comparative effectiveness research in inflammatory bowel disease.
Dulai PS
J Gastroenterol Hepatol; 2021 Apr; 36 Suppl 1():16-17. PubMed ID: 33817857
[No Abstract] [Full Text] [Related]
3. Advanced therapies in inflammatory bowel disease: Special considerations.
Williams AJ
J Gastroenterol Hepatol; 2021 Apr; 36 Suppl 1():22-24. PubMed ID: 33817851
[No Abstract] [Full Text] [Related]
4. Safety comparison of therapies used in inflammatory bowel disease.
Pudipeddi A
J Gastroenterol Hepatol; 2021 Apr; 36 Suppl 1():20-21. PubMed ID: 33817854
[No Abstract] [Full Text] [Related]
5. Comparative Analysis of the 3-Year Persistence Rate with Second-Line Vedolizumab and Tumor Necrosis Factor-α Inhibitors in Patients with Inflammatory Bowel Disease Followed in Gastroenterology Practices in Germany.
Helwig U; Braegger F; Kostev K; Schmidt C
Dig Dis; 2020; 38(6):466-473. PubMed ID: 32045927
[TBL] [Abstract][Full Text] [Related]
6. New choices, new challenges: Anti-TNF versus anti-integrin molecule therapy in IBD.
van Langenberg DR
J Gastroenterol Hepatol; 2016 Jun; 31 Suppl 1():10-1. PubMed ID: 26990680
[No Abstract] [Full Text] [Related]
7. Antitumor necrosis factor, infliximab, and adalimumab: use with caution in eosinophilic bowel disease.
Furuta GT; Atkins D; Capocelli KE; de Zoeten EF; Fleischer D; Menard-Katcher C
J Pediatr Gastroenterol Nutr; 2013 Oct; 57(4):e25. PubMed ID: 23820407
[No Abstract] [Full Text] [Related]
8. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists.
Mitoma H; Horiuchi T; Tsukamoto H; Ueda N
Cytokine; 2018 Jan; 101():56-63. PubMed ID: 27567553
[TBL] [Abstract][Full Text] [Related]
9. The Era of Anti-Tumor Necrosis Factor Is Over. What Do We Know, What Don't We Know, and What Do We Yearn to Know?
Dwadasi S; Israel A; Rubin DT
Gastrointest Endosc Clin N Am; 2019 Jul; 29(3):405-419. PubMed ID: 31078244
[No Abstract] [Full Text] [Related]
10. Clinical and scientific aspects related to biosimilars in inflammatory bowel diseases (IBD): position document of the Belgian IBD Research & Development Group (BIRD).
Vermeire S; Louis E; Dewit O; Franchimont D; Moreels T; Ferrante M; Rahier JF; Van Hootegem P; De Vos M; Mana F; Baert F;
Acta Gastroenterol Belg; 2015; 78(1):26-9. PubMed ID: 26118575
[No Abstract] [Full Text] [Related]
11. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.
Gisbert JP; Chaparro M
J Crohns Colitis; 2020 Jun; 14(5):694-709. PubMed ID: 31777929
[TBL] [Abstract][Full Text] [Related]
12. "Paradoxical" arthralgia occurring under anti-TNFα treatment for inflammatory bowel disease.
Sondag M; Verhoeven F; Guillot X; Prati C; Briot C; Vuitton L; Koch S; Wendling D
Joint Bone Spine; 2018 Jan; 85(1):133-134. PubMed ID: 28115270
[No Abstract] [Full Text] [Related]
13. [TNF-alpha blocking therapy in chronic inflammatory bowel disease].
Molnár T
Orv Hetil; 2009 Sep; 150(38):1773-9. PubMed ID: 19740722
[TBL] [Abstract][Full Text] [Related]
14. A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease.
Aardoom MA; Veereman G; de Ridder L
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126015
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs.
Thorlund K; Druyts E; Toor K; Mills EJ
Expert Rev Gastroenterol Hepatol; 2015 May; 9(5):693-700. PubMed ID: 25763862
[TBL] [Abstract][Full Text] [Related]
16. [Patient information. Biological agents in inflammatory bowel disease].
Van Domselaar M
Rev Esp Enferm Dig; 2008 Dec; 100(12):798. PubMed ID: 19238770
[No Abstract] [Full Text] [Related]
17. Anti-tumor necrosis factor agents and placental transfer: relevant clinical data for rational decision-making.
Kane S
Clin Gastroenterol Hepatol; 2013 Mar; 11(3):293-4. PubMed ID: 23247325
[No Abstract] [Full Text] [Related]
18. The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease.
Seow CH; Leung Y; Vande Casteele N; Ehteshami Afshar E; Tanyingoh D; Bindra G; Stewart MJ; Beck PL; Kaplan GG; Ghosh S; Panaccione R
Aliment Pharmacol Ther; 2017 May; 45(10):1329-1338. PubMed ID: 28318043
[TBL] [Abstract][Full Text] [Related]
19. [Application of TNF-alpha blocker concentration assays in the treatment of inflammatory bowel diseases].
Sipponen T; Kolho KL
Duodecim; 2013; 129(5):499-505. PubMed ID: 23520893
[TBL] [Abstract][Full Text] [Related]
20. Comparison of drug survival between infliximab and adalimumab in inflammatory bowel disease.
Gil-Candel M; Gascón-Cánovas JJ; Urbieta-Sanz E; Rentero-Redondo L; Onteniente-Candela M; Iniesta-Navalón C
Int J Clin Pharm; 2020 Apr; 42(2):500-507. PubMed ID: 32006141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
